The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive genomic profiling of squamous cell carcinoma of unknown primary presenting with liver metastases.
 
Hannah Ruth Robinson
No Relationships to Disclose
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Dean C. Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Karthikeyan Murugesan
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
Patents, Royalties, Other Intellectual Property - Analytic prediction of antibiotic susceptibility (US20190279738A1) filed with Koninklijke Philips NV (Inst); Antibiotic resistance causation identification (US10629291B2) filed with Koninklijke Philips NV (Inst); CD274 rearrangements as predictors of response to immune checkpoint inhibitor therapy, WO2023064784A1, filed with Foundation Medicine Inc. (Inst); Methodology for measuring the quality of phylogenetic and transmission trees and for merging trees (US20200357491A1) filed with Koninklijke Philips NV (Inst); Methods and devices for characterizing and treating combined hepatocellular cholangiocarcinoma, PCT/US2022/014148, filed with Foundation Medicine Inc. (Inst); Methods of using somatic HLA-I loss of heterozygosity to predict response to immune checkpoint inhibitor-treated patients with lung cancer, PCT/US2022/073166, filed with Foundation Medicine Inc. (Inst)
Travel, Accommodations, Expenses - Foundation Medicine
 
Katy Ann Wong
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Elaine T. Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Merck (Inst)